Is Your Life Sciences Patent Enabled? The U.S. Supreme Court Is Considering That Question
The U.S. Supreme Court is considering whether an Amgen patent–which claims antibodies by functional antigen binding and does not disclose the full range of antibody sequences–is invalid for not meeting the enablement requirements of Section 112(a). Three Procopio IP Partners–experts in patent prosecution and patent litigation–discuss the background of the case, in particular how the High Court’s decision may impact the ability to obtain certain life science, chemical and pharma patents and how it may provide additional ammunition to attack such patents in patent litigation.
In this podcast episode you’ll hear from:
- Jeff Morton, PhD, IP Partner and Life Sciences group leader (San Diego)
- Robert “Bob” Sloss, IP Litigation Partner (Palo Alto)
- Jeremy Edwards, IP Litigation Partner (Washington, D.C.)
Click below on “VIEW PDF” to read the transcript or “PLAY NOW” to hear the podcast.
- 00:51: A patent prosecution attorney perspective on the case.
- 02:26: A patent litigation attorney perspective on the case.
- 03:27: Background on the scientific issues involved.
- 06:47: The litigation backstory.
- 10:00: A look at the robustness of the patents in question.
- 12:50: Thoughts on the U.S. Supreme Court stepping in.
- 15:20: Why the case is important to patent prosecutors.
- 21:13: Why the case is important to patent litigators.